Full-Time
Confirmed live in the last 24 hours
Advanced cardiac monitoring solutions provider
$76.3k - $90kAnnually
Senior
Remote in USA
Remote work is available, but the job is focused on the northern part of New Jersey.
You match the following iRhythm Technologies's candidate preferences
Employers are more likely to interview you if you match these preferences:
iRhythm Technologies specializes in cardiac monitoring solutions, primarily through its product, the Zio Patch. This wearable device allows for up to 14 days of continuous heart rhythm tracking, enabling healthcare providers to detect irregular heart rhythms that may not be identified during shorter monitoring periods. The Zio Patch is particularly useful for patients who suspect heart rhythm issues, as it allows them to monitor their heart activity without frequent visits to healthcare facilities, which is especially important in the context of telehealth and COVID-19. Unlike many competitors, iRhythm not only provides the monitoring device but also offers data analysis services that interpret the collected data, giving healthcare providers actionable insights. The company's goal is to enhance patient outcomes and improve healthcare workflows by making cardiac monitoring more accessible and efficient.
Company Size
1,001-5,000
Company Stage
IPO
Total Funding
$102.8M
Headquarters
San Francisco, California
Founded
2006
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Mental Health Support
Hybrid Work Options
Pet Insurance
iRhythmSAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 43rd Annual J.P. Morgan Healthcare Conference.Recent Operational Highlights and Financial OutlookAnticipate full year 2024 revenue slightly above high end of previously stated guidance range of $587.5 million provided in October 2024Record quarter of new account openings for both Zio monitor and Zio AT during the fourth quarter 2024 as well as strong volume contributions from large national accountsLaunched first four health care systems on Epic Aura during the fourth quarter 2024 with broad commercial roll out for Epic health systems across the U.S. beginning in 2025Initiated Zio monitor shipments for home enrollment patients during the fourth quarter 2024Five studies presented at the American Heart Association highlight Zio Monitor’s high patient satisfaction, engagement and compliance with the patient MyZio app and digital tools, health economic impact of early arrhythmia detection in type 2 diabetes and respiratory disease, and AI insights on sleep and activity patterns 1Expect revenue for the full year 2025 of approximately $675 million to $685 million“This past year was a period of significant growth and transformation for iRhythm,” said Quentin Blackford, iRhythm’s President and CEO. “In our core U.S
Dynamic Technology Lab Private Ltd invests $1.50 million in iRhythm Technologies, Inc. (NASDAQ:IRTC).
The letter accused iRhythm of violating Federal Food, Drug, and Cosmetic Act rules about labeling, medical device reporting, and quality systems.
Recently a securities fraud complaint was filed against iRhythm on behalf of investors who purchased shares of the company's stock between November 5, 2021 and May 30, 2023 (the "Class Period").
iRhythm Technologies announced that the company has signed an exclusive license agreement with BioIntelliSense, a continuous health monitoring and clinical intelligence company, to develop and commercialize certain patented technology assets within ambulatory cardiac monitoring, ACM.